Articles tagged with Fatty Liver Disease
A novel 3D imaging technique reveals the degeneration of nerves in the liver, correlating with the severity of liver pathology in non-alcoholic fatty liver disease. The study suggests a 'vicious cycle' where compromised nerve function contributes to disease progression and worsens metabolic challenges.
Researchers found that a chemical modification called m6A may offer protection against non-alcoholic fatty liver by slowing down the accumulation of fat in the liver. The study also suggested that this modification occurs at a different rate in females than males, potentially explaining sex differences in liver fat content.
A new noninvasive biomarker, thrombospondin-2, can identify patients at risk of NAFLD complications using a simple blood test. The biomarker was found to parallel clinical indicators used to categorize pathological changes in liver cells.
A two-year study found that testosterone therapy normalised testosterone levels, reduced NAFLD, and suppressed symptoms of hypogonadism in obese men. Testosterone therapy may help obese men with functional hypogonadism and type-2 diabetes reduce the prevalence of non-alcoholic fatty liver disease.
A new study found that blocking ABCB10 protein in liver cells protects against insulin resistance and fatty liver disease. Increased bilirubin content inside mitochondria driven by ABCB10 activity contributes to fatty liver disease. The findings could inspire the development of therapies targeting ABCB10 or mitochondrial bilirubin.
A team of scientists at Cincinnati Children's Hospital Medical Center has discovered a promising new approach to preventing obesity-driven liver damage. By controlling a subgroup of immune system cells that trigger non-alcoholic fatty liver disease (NAFLD), researchers have identified a potential treatment target.
A new registry study linked non-alcoholic fatty liver (NAFLD) to a 17-fold increased risk of liver cancer, particularly hepatocellular carcinoma. NAFLD patients were also found to have a higher risk of other cancers, emphasizing the need for targeted interventions and personalized screening strategies.
Researchers developed a chimeric mouse model that accurately reproduces human non-alcoholic fatty liver disease (NAFLD) by combining both human and murine cells. The study reveals striking differences in liver cell behavior, metabolism, and gene expression, providing new insights into the disease's mechanisms.
A study published in International Journal of Environmental Research and Public Health found that exercise can alter the oral environment, favoring less harmful bacteria in people with NAFLD and gum disease. This shift may help reduce inflammation and improve overall health outcomes.
Researchers at the University of Tsukuba found that exercise regimen reduced liver steatosis by 9.5%, liver stiffness by 6.8%, and FibroScan-AST Score by 16.4%. Exercise preserved muscle mass, independent of weight loss, and induced anti-inflammatory responses.
A review of studies links excessive fructose intake to NAFLD in children, suggesting restricting added sugars may reduce risk; current diagnosis methods are inadequate, and better tools are needed.
Researchers at Tokyo University of Science have developed a new method to quantify fat content in liver tissue using near-infrared hyperspectral imaging. The study found that this technique can accurately visualize lipid distributions within the liver and identify fatty liver-associated liver diseases, including cancer.
A new study from the University of Minnesota Medical School suggests that disease-driving B cells contribute to the development of non-alcoholic fatty liver disease (NAFLD). The research, led by Fanta Barrow, found that a Western diet and changes in gut microbes activate these pathogen-fighting B cells into 'disease-promoters',
Researchers have identified CNNM4 protein as key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease. High expression of CNNM4 protein is associated with inflammation and liver fibrosis in patients with non-alcoholic steatohepatitis.
Researchers developed a stem cell-based cell culture model for nonalcoholic fatty liver disease (NAFLD), revealing key findings on gene expression, lipid droplet morphology, and metabolic networks. The model also showed promising results with AdipoRon, a synthetic analogue that positively influences hepatocyte metabolism.
A study published in the American Journal of Roentgenology found that multiparametric CT findings can distinguish patients with high-risk NAFLD, characterized by advanced fibrosis or cirrhosis. However, the presence of nonalcoholic steatohepatitis (NASH) remains elusive on CT.
The study found that the green Mediterranean diet resulted in the greatest reduction of hepatic fat, with participants experiencing dramatic reductions in fatty liver. The modified diet included high intake of walnuts and Mankai, as well as less red meat.
Researchers found that a protein called Cx43 allows stress signals from one liver cell to spread to neighboring cells, causing dysfunction. Mice with deleted Cx43 were protected from insulin resistance, glucose intolerance, and non-alcoholic fatty liver disease.
A new study suggests a link between low levels of glycine and nonalcoholic fatty liver disease (NAFLD), potentially leading to novel treatment options. Researchers found that improving body composition and glutathione synthesis with a tripeptide called DT-109 could attenuate experimental NAFLD.
Researchers found that triclosan disrupts metabolism and the gut microbiome, leading to accelerated development of fatty liver and fibrosis. The study provides new insights into risk factors for non-alcoholic fatty liver disease (NAFLD) in humans.
Researchers will investigate the role of Cyp2b genes, human CYP2B6 gene, and environmental toxicants like PFOS in obesity and fatty liver disease. The study aims to understand complex interactions between diet, fat stores, and genetic factors.
A recent study by University of Jyväskylä researchers found that a dietary supplement increased the growth of good bacteria in rats' gut, leading to reduced liver fat content and improved glucose metabolism. Preliminary results from human studies with fatty liver disease patients also seem promising.
A nationwide cohort study has confirmed that non-alcoholic fatty liver disease (NAFLD) is associated with increased mortality risk, even in mild stages. The study found that patients with NAFLD had a 93% increased risk of all-cause mortality, driven primarily by deaths from extra-hepatic cancer and cirrhosis.
Yale researchers found a molecular connection between nonalcoholic fatty liver disease and liver insulin resistance. They identified diacylglycerols and ceramides as key players in this process.
A new study found that obesity-related illnesses frequently occur in people with a BMI over 30, yet only 9% had obesity recorded as a cause of death. Researchers argue that obesity is not being accurately documented on medical certificates, highlighting the need for further studies.
A pilot study found that assessing liver fibrosis in people with type 2 diabetes could identify large numbers of previously undiscovered cases of advanced liver disease, increasing diagnosis rates 5-fold. The study also discovered that over half of patients diagnosed with significant fibrosis had normal ALT levels.
Children born to obese mothers face higher risk of developing non-alcoholic fatty liver disease due to microbiome disruption, which can be influenced by maternal diet during pregnancy. The study aims to investigate the role of pyrroloquinoline quinone in improving the microbiome and lowering the risk for NAFLD.
A study published in JCI Insight has identified a potential treatment for non-alcoholic fatty liver disease (NAFLD), with tesamorelin reducing liver fat and fibrosis progression. The drug appears to increase expression of genes associated with burning of fat in the mitochondria, which may prevent fibrosis.
New studies demonstrate significant reductions in ALT, hepatic fat, and liver damage biomarkers for patients with non-alcoholic steatohepatitis (NASH). The treatments target lipid metabolism and show potential to address type 2 diabetes and obesity.
A new study published in Nature Metabolism suggests that excessive fructose consumption can lead to a leaky gut and subsequently cause fatty liver disease. The researchers found that the high fructose corn syrup disrupts the epithelial barrier protecting internal organs from bacterial toxins, leading to chronic inflammatory conditions.
Researchers developed a new microscopy technique to visualize NAFLD progression in real-time, capturing details of lipid accumulation and immune cell behavior. The approach provides a highly useful research tool for identifying key parameters contributing to the disease.
A high-protein diet with a calorie-reduced intake was found to decrease liver fat by around 40% in obese individuals with non-alcoholic fatty liver disease. The study suggests that the positive effect of the high-protein diet is due to suppressed uptake, storage, and synthesis of fat in the liver.
A review article suggests postmenopausal women are at higher risk for developing nonalcoholic fatty liver disease (NAFLD) due to the decline in estrogen levels. Normal-weight women with normal lipid, glucose, and insulin levels are at low risk for NAFLD.
Researchers at UPV/EHU University of the Basque Country discover osteopontin's protective role in preventing early onset of metabolic fatty liver disease. Maintaining physiological levels of osteopontin is essential to delay disease progression during ageing.
Non-alcoholic fatty liver disease (NAFLD) affects both obese and non-obese individuals, with distinct differences found in male and female patients of varying body mass indexes. Key findings include lower skeletal muscle mass and insulin resistance in non-obese NAFLD patients compared to their obese counterparts.
A Wayne State University team has made significant breakthroughs in understanding the causal relationships between nonalcoholic fatty liver disease (NAFLD), type-2 diabetes, and obesity. They discovered two subtypes of NAFLD: one caused by genetic factors and another driven by metabolic syndrome.
Australian experts warn of a surge in chronic liver disease due to alcohol misuse and obesity-related liver disease. The number of cases has increased three-fold over the past 10-15 years, with over 6 million Australians affected.
Researchers have discovered a new target and therapy to fight NAFLD, a major health issue affecting 25% of the world population. Using siRNA to silence MCJ protein, they found reduced liver steatosis and fibrosis in preclinical mouse models.
A recent study reveals the cause behind the link between non-alcoholic fatty liver disease and neurological problems, including Alzheimer's disease-like symptoms. The unique role of an adipokine called Lipocalin-2 in causing neuroinflammation may explain the prevalence of MAFLD among individuals with neurological disorders.
A new study uses stool microbiomes to predict cirrhosis risk in patients with nonalcoholic fatty liver disease. Researchers found a unique signature that distinguishes cirrhosis from other causes of the disease, potentially leading to an accurate, non-invasive diagnostic tool.
A Phase II trial found that the treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression to non-alcoholic steatohepatitis. The study showed robust reduction in liver fat without corresponding increases in blood lipids.
Women with non-alcoholic fatty liver disease (NAFLD) in pregnancy face increased risks of maternal and infant health complications. The study found that NAFLD is associated with hypertensive complications, preterm birth, and maternal bleeding after delivery, independent of other metabolic diseases.
A new study found that fecal transplants can reduce intestinal permeability in patients with non-alcoholic fatty liver disease (NAFLD), a condition associated with metabolic syndrome and autoimmune diseases. The treatment shows promise for improving gut health and preventing further inflammation.
Researchers found an unexpected connection between electron imbalance in liver cells and many metabolic problems, including cardiovascular disease and fatty liver disease. The study identified a biomarker, alpha-hydroxybutyrate, to test for reductive stress and suggests LbNOX as a potential treatment.
Scientists from GIST developed a novel peripheral serotonin antagonist, which showed promising results in obese mice with impaired liver function. The compound improved symptoms of fatty liver disease and reduced body fat. Researchers hope the drug candidate will offer relief to patients with nonalcoholic fatty liver disease.
Researchers have identified three new genes that play a role in preventing fatty liver development. The genes IRGM, Ifgga2, and Ifgga4 produce regulatory proteins that counteract fat accumulation in the liver, but genetic variations lead to reduced protein production, resulting in increased fat content.
Recent studies on NAFLD have made significant progress in understanding the risk factors, diagnosis, and treatment of the condition. The latest research emphasizes the importance of gut microbiota modulation to improve severity, as well as the role of hepatic inflammatory pathways in driving comorbidities.
NAFLD affects 5.7% of adults in the US, progressing to cirrhosis in 39% over 8 years, with risk factors including cardiovascular disease and high cholesterol.
A new study led by Dr. Rohit Kohli shows that stevia extract can reduce markers of fatty liver disease, improving glucose levels and reducing cellular stress. The findings suggest potential benefits for pediatric patients with non-alcoholic fatty liver disease.
A study published at Digestive Disease Week found that nearly 83% of 9/11 first responders had fatty liver disease, compared to 24-45% in the general population. The research highlights the link between toxin exposure and non-alcoholic fatty liver disease among first responders.
Researchers from Joslin Diabetes Center have identified a potential early biomarker for non-alcoholic fatty liver disease (NAFLD), which is linked to the regulation of liver fat metabolism and fibrosis. The protein NREP was found to decrease in levels as NAFLD progressed, suggesting its role as an early indicator of the disease.
Researchers found that bariatric surgery significantly decreased liver enzymes, Fatty Liver Index, and BARD score in patients with NAFLD. Gastric bypass was associated with the greatest reduction in liver damage.
Researchers redefine Non-Alcoholic Fatty Liver Disease (NAFLD) as Metabolic Associated Fatty Liver Disease (MAFLD), a condition characterized by liver fat build-up affecting over 1 billion people. The new definition aims to improve treatment pathways, trial design, and drug development for this disease.
A ketogenic diet reduced liver fat content and improved insulin resistance in overweight participants. The diet also increased hydrolysis of triglycerides and promoted ketogenesis, suggesting a possible mechanism for reversing nonalcoholic fatty liver disease.
Yale scientists have discovered the molecular mechanisms that trigger metabolic imbalance between glucose production and energy utilization in the liver. They found that a protein called INSP3R1 regulates both gluconeogenesis and fat oxidation in response to glucagon, providing new insights into glucagon biology.
A novel cause of fatty liver disease has been discovered in lean individuals undergoing immune checkpoint blockade therapy. Researchers report a case of a woman who experienced severe inflammation of her subcutaneous fat and developed nonalcoholic fatty liver disease after treatment with the PD-1 inhibitor Nivolumab.
Researchers found that green tea extract and exercise reduced fatty liver deposits by 75% in mice fed a high-fat diet, suggesting a potential health strategy for people. The study also showed increased gene expression related to energy metabolism in mice treated with both green tea extract and exercise.
A recent study published in the journal AIDS found that vitamin E improves liver function and reduces fat in patients with nonalcoholic steatohepatitis (NASH) and HIV. The treatment was well-tolerated and showed more significant improvements than reported in the general population.
Researchers have discovered that indole, a natural compound found in gut bacteria and cruciferous vegetables, can reduce inflammation and fatty deposits in the liver. This study provides hope for new treatments and preventive measures for non-alcoholic fatty liver disease (NAFLD).
Researchers developed a small molecule drug CTPI-2 that targets Slc25a1 gene involved in lipid and glucose metabolism, preventing liver damage, obesity and glucose intolerance in mice. The study showed promising results, confirming the importance of this gene in fatty liver disease.